Discussion Eculizumab is an excellent drug for treating aHUS, with an overall favorable risk
profile [1, 2]. However, several issues remain to be addressed with respect to life-long …

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening
thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab …

Background Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic
microangiopathy characterized by uncontrolled activation of the alternative complement …

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …

Introduction Eculizumab is effective treatment of pediatric atypical hemolytic uremic
syndrome (aHUS). However, the optimal duration of treatment is not clearly defined. The aim …

Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome
(aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children …

Background There are limited long-term outcome data in eculizumab-treated patients with
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …

Atypical hemolytic uremic syndrome (aHUS) is an ultrarare disease caused, in most cases,
by dysregulation of the alternative complement (C′) pathway at the surface of the vascular …

Introduction Studies relating to first-line, early, and long-term eculizumab treatment and
outcomes in children with atypical hemolytic uremic syndrome (aHUS) are scarce and …

Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …